Roche Holding AG / IQuum, Inc.

Infectious disease point-of-care molecular diagnostics (Influenza A/B, Strep A)

Disease Overview

Acute respiratory infections (influenza, Group A streptococcal pharyngitis) drive tens of millions of US outpatient encounters every year. Rapid molecular identification of the pathogen at point-of-care enables timely antiviral or antibiotic stewardship and reduces empiric prescribing in physician offices, urgent care and ER settings.

Competitive Landscape

Point-of-care molecular diagnostics in 2014 was a fast-emerging segment dominated by Cepheid's GeneXpert (centralized but workflow-friendly), Alere/Abbott's i (immunoassay-based rapid tests), and BioFire's FilmArray (just acquired by bioMerieux in January 2014 for $450M). IQuum's cobas Liat with FDA-cleared and CE-marked Influenza A/B and Strep A assays gave Roche a true CLIA-waivable, sub-30-minute PCR platform that competitors lacked at decentralized sites. Pre-acquisition, Roche's molecular diagnostics franchise was anchored by high-throughput cobas 4800/6800/8800 systems for centralized labs, leaving the physician-office and ER niche unserved. The DeciBio analysis framed the deal as Roche filling 'a glaring hole' in its MDx portfolio and matching the bioMerieux-BioFire move. Strategically, the acquisition pre-positioned Roche for what later became a critical respiratory POC market - the cobas Liat platform was widely deployed during the COVID-19 pandemic with SARS-CoV-2 assays, validating the 2014 thesis. The deal changed the competitive map: Roche could now bracket Cepheid and Alere across throughput tiers within a single brand, a structural advantage in IDN contracting.